---

CRITICAL ANALYSIS OF SPECIAL CONSIDERATIONS IN TREATMENT OF AGGRESSIVE FORMS OF PERIODONTAL DISEASE

---

⚠️ RECENT TERMINOLOGY CHANGES (EXAMINER CRITICAL POINT)

In the 2018 classification, both chronic and aggressive periodontitis as categories were combined. The 2018 classification adopted an approach in which previous "chronic" or "aggressive" periodontitis are now described using staging and grading. The term "aggressive periodontitis" was employed to define rampant progression and lack of local factors. In the 2018 classification, both chronic and aggressive periodontitis are now described as one entity - "periodontitis" - differentiated by stage and grade.

---

SECTION I: WHY AGGRESSIVE PERIODONTITIS REQUIRES SPECIAL CONSIDERATION IN TREATMENT

1.1 Unpredictable Response to Conventional Therapy

• "Aggressive periodontitis, by definition, causes rapid destruction of the periodontal attachment apparatus and the supporting alveolar bone."
• "The responsiveness of aggressive periodontitis to conventional periodontal treatment is unpredictable, and the overall prognosis for these patients is poorer than for patients with chronic periodontitis."
• Because these patients do not respond "normally" to conventional methods and their disease progresses unusually fast, the logical question is whether there are problems associated with an impaired host immune response that may contribute to such a different disease and result in a limited response to the usual therapeutic measures.

1.2 Host Immune Defects

• "Defects in polymorphonuclear leukocyte (PMN, neutrophil) function have been identified in some patients with aggressive periodontitis."
• In a small number of cases, a systemic disease such as neutropenia can be identified.
• In most patients with aggressive periodontitis, however, systemic diseases or disorders cannot be identified. "In fact, the irony is that these patients are typically quite healthy."
• Numerous attempts to examine immunologic profiles have failed to identify any specific etiologic factors common to all patients.

1.3 Tissue-Invasive Bacteria

• "It is especially important to consider antibiotic therapy in the treatment of aggressive periodontitis, which often involves several specific pathogens with the potential to invade pocket epithelium and connective tissue."
• The presence of A. actinomycetemcomitans in the gingival biopsies taken from sites adjacent to periodontal lesions is a critical feature that makes mechanical therapy alone insufficient.
• The localization of bacteria within gingival tissues from various forms of aggressive periodontitis decreases the efficacy of mechanical debridement alone.

1.4 Familial Aggregation

• "Aggressive periodontitis aggregates strongly in families."
• "Educating family members is another important factor because aggressive periodontitis is known to have familial aggregation. Thus, family members, especially younger siblings, of the patient diagnosed with aggressive periodontitis should be examined for signs of disease, educated about preventive measures, and monitored closely."

---

SECTION II: PROGNOSIS - A SPECIAL CONSIDERATION

2.1 Determinants of Prognosis

1. Whether the disease is generalized or localized
2. The degree of destruction present at the time of diagnosis
3. The ability to control future progression

2.2 Prognosis: LAP vs. GAP

• "Cases of localized aggressive periodontitis often have a limited period of rapid periodontal attachment and alveolar bone loss, followed by a slower, more chronic phase of disease progression."
• This unexplained curtailment of disease progression has sometimes been referred to as "burnout" of the disease.

---

SECTION III: ESSENTIAL THERAPEUTIC CONSIDERATIONS (Examiner Keywords)

1. Control the infection
2. Arrest disease progression
3. Correct anatomic defects
4. Replace missing teeth
5. Help the patient maintain periodontal health with frequent periodontal maintenance care

---

SECTION IV: EARLY DETECTION AND DIAGNOSIS

• "Early detection is critically important in the treatment of aggressive periodontitis (generalized or localized) because preventing further destruction is often more predictable than attempting to regenerate lost supporting tissues."
• At the initial diagnosis, it is helpful to obtain any previously taken radiographs to assess the rate of progression of the disease.
• "Early diagnosis, intervention, and, if possible, prevention of disease are more desirable than attempting to reverse the destruction that results from aggressive periodontitis."
• Comparing serial radiographs is essential for assessment of treatment success and control of the disease.

---

SECTION V: PATIENT EDUCATION AND ORAL HYGIENE

• "One of the most important aspects of treatment success is to educate the patient about the disease, including the causes and the risk factors for disease, and to stress the importance of the patient's role in the success of treatment."
• The discrepancy between clinical appearance (good oral hygiene) and severity of destruction is a hallmark of AgP. "Lack of consistency between clinically visible bacterial deposits and severity of periodontal breakdown" is a primary criterion.
• Despite good plaque control, patients must understand that their disease may still progress due to host susceptibility factors.

---

SECTION VI: DIAGNOSIS CRITERIA - SPECIAL CLINICAL CONSIDERATION

1. Absence of significant systemic conditions
2. Rapid attachment loss and bone destruction
3. Familial aggregation of cases
4. Lack of consistency between clinically visible bacterial deposits and severity of periodontal breakdown

Differential Diagnosis: LAP vs. GAP

---

SECTION VII: CONVENTIONAL PERIODONTAL THERAPY

7.1 Components

1. Patient education
2. Oral hygiene improvement
3. Scaling and root planing
4. Regular (frequent) recall maintenance
5. May or may not include periodontal flap surgery"

7.2 Limitations of Conventional Therapy Alone

• "The response of aggressive periodontitis to conventional therapy alone has been limited and unpredictable."
• Patients diagnosed at an early stage have a better outcome than those diagnosed at an advanced stage.
• "In general, the earlier the disease is diagnosed, the more conservative the therapy and the more predictable the outcome."

---

SECTION VIII: FULL-MOUTH DISINFECTION PROTOCOL (Special Consideration)

• A few reports have included patients with aggressive (early-onset) periodontitis in the evaluation of the one-stage full-mouth disinfection protocol.
• De Soete et al. found a significant reduction in probing pocket depth and gain in clinical attachment in patients with aggressive periodontitis up to 8 months after treatment compared with controls (scaling and root planing by quadrant at 2-week intervals).
• Significant reductions in periodontal pathogens were found up to 8 months after therapy. Porphyromonas gingivalis and Tannerella forsythia (formerly Bacteroides forsythus) were reduced to levels below detection.

---

SECTION IX: ANTIBIOTIC THERAPY - THE CORNERSTONE OF SPECIAL CONSIDERATION

9.1 Rationale for Mandatory Antibiotic Adjunct

1. Tissue-invasive bacteria: "Mechanical removal of calculus and plaque from root surfaces may not eliminate this bacterium (A. actinomycetemcomitans) from the periodontal tissues. Systemic tetracycline can eliminate tissue bacteria." - The bacterium invades tissue and therefore cannot be mechanically removed.
2. Biofilm resistance: Bacteria organized in biofilms are less susceptible to antimicrobials unless there is a previous disruption by mechanical debridement.
3. Virulence of microflora: The discrepancy between local factors and the amount of tissue breakdown indicates either infection with particularly virulent microorganisms or presence of a highly susceptible host.
4. Evidence from meta-analyses: Meta-analyses of randomized clinical trials and quasi-experimental studies have shown that systemic antibiotics can improve attachment levels when used as adjuncts to root instrumentation.

9.2 Critical Principle: Antibiotics Must Precede Mechanical Debridement or be Simultaneous

1. We should quantitatively reduce the large mass of bacteria, which otherwise may inhibit or degrade the antimicrobial agent. Insufficient concentrations of the active agent may again favor the emergence of resistant strains.
2. We should mechanically disrupt the structured bacterial aggregates that can protect the bacteria from the agent."

• Indirect evidence suggests that antibiotic intake should start on the day of debridement completion; debridement should be completed within a short time (preferably 1 week).

---

SECTION X: SPECIFIC ANTIBIOTIC REGIMENS

TABLE: Antibiotics Used to Treat Periodontal Diseases (AgP-Specific Indications)

TABLE: Common Antibiotic Regimens for AgP (Newman & Carranza 14th Ed., Table 53.2)

---

SECTION XI: TETRACYCLINES - ROLE AND LIMITATIONS

11.1 Rationale for Tetracycline Use in AgP

• "Tetracyclines have the ability to concentrate in the periodontal tissues and inhibit the growth of Aggregatibacter actinomycetemcomitans."
• "Tetracyclines exert an anticollagenase effect that can inhibit tissue destruction and may help with bone regeneration."
• Tetracyclines at a low GCF concentration (i.e., 2 μg/mL to 4 μg/mL) are very effective against many periodontal pathogens.
• Concentration in GCF is 2 to 10 times that found in serum - allows high drug concentration to be delivered into periodontal pockets.

11.2 Classic Studies on Tetracycline in LAP

• Genco et al. treated LAP patients with SRP + systemic tetracycline (250 mg four times daily for 14 days every 8 weeks) - Bone loss had stopped, and one third of the defects demonstrated an increase in bone level (up to 18 months).
• Liljenberg and Lindhe treated LAP with tetracycline (250 mg four times daily for 2 weeks) + modified Widman flaps + periodic recall. "Lesions healed more rapidly and more completely than similar lesions in control patients." At 5 years: continued resolution of gingival inflammation, gain of clinical attachment, and refill of bone in angular defects.
• Christersson et al. showed systemic tetracycline-HCl alone suppressed A. actinomycetemcomitans, but A. actinomycetemcomitans was suppressed below detectable levels in only approximately 50% of the lesions even following an 8-week administration.

11.3 Limitations and Current Status of Tetracyclines

• Long-term use of low antibacterial doses of tetracyclines is not advisable due to the possible development of resistant bacterial strains.
• A long-term study: patients taking low doses (250 mg/day for 2-7 years) showed persistence of deep pockets containing high proportions of tetracycline-resistant gram-negative rods (Fusobacterium nucleatum).
• "Although tetracyclines were often used in the past as anti-infective agents, especially for LAP and other types of aggressive periodontitis, they are now frequently replaced by more effective combination antibiotics."

BOX 46-1 (Carranza's 10th Ed.): Systemic Tetracycline in Treatment of Aggressive Periodontitis

---

SECTION XII: COMBINATION ANTIBIOTIC THERAPY - CURRENT GOLD STANDARD

12.1 Metronidazole + Amoxicillin: The Preferred Combination

• Guerrero et al. revealed that in patients with GAP after systemic antibiotics consisting of 500 mg amoxicillin and 500 mg metronidazole three times a day for 7 days, there were highly significant treatment effects for full-mouth PPD reduction at 2 and 6 months:
  • PPD reduction at 4-6 mm pockets: adjusted differences of 0.5 mm at 2 months, 0.4 mm at 6 months
  • PPD reduction at ≥7 mm pockets: 0.9 mm at 2 months, 1.4 mm at 6 months
  • CAL gain at sites with initial PPD ≥7: 0.6 mm at 2 months, 1.0 mm at 6 months
• Haffajee et al. concluded that a systemically administered combination of antibiotics (amoxicillin and metronidazole) with periodontal therapy provided better disease control in difficult-to-manage periodontitis cases than similar periodontal therapy without antibiotics.

12.2 Amoxicillin + Clavulanate (Augmentin)

• "Some investigators think that metronidazole in combination with amoxicillin-clavulanic acid is the preferable antibiotic."
• Bueno and colleagues reported that Augmentin arrested alveolar bone loss in patients with periodontal disease that was refractory to treatment with other antibiotics, including tetracycline, metronidazole, and clindamycin.

12.3 Metronidazole + Ciprofloxacin

• The combination of metronidazole and ciprofloxacin is particularly useful when A. actinomycetemcomitans is resistant to the amoxicillin + metronidazole combination.
• Ciprofloxacin: "Effective against gram-negative rods; promotes health-associated microflora."
• Dose: 500 mg of each, twice daily for 8 days.

12.4 Penicillin-Allergy Special Consideration

---

SECTION XIII: GUIDELINES FOR USE OF ANTIBIOTICS IN AgP

1. The clinical diagnosis and situation dictate the need for possible antibiotic therapy as an adjunct for controlling active periodontal disease.
2. Disease activity as measured by continuing attachment loss, purulent exudate, and bleeding on probing may be an indication for periodontal intervention and possible microbial analysis through plaque sampling.
3. When used to treat periodontal disease, antibiotics are selected on the basis of the patient's medical and dental status, current medications, and the results of microbial analysis, if performed.
4. Microbiologic plaque sampling may be performed - endodontic paper point inserted subgingivally into deepest pockets.
5. Systemic antibiotics improve attachment levels when used as adjuncts to root instrumentation. The same benefits could not be demonstrated when antibiotics were used as stand-alone therapy.
6. When systemic antibiotics were used as adjuncts to SRP, patients with aggressive periodontitis experienced greater benefits than patients with chronic periodontitis. The mean attachment level change ranged from 0.09 mm to 1.10 mm.
7. "The more severe the disease and the deeper the pocket, the better the response to antibiotic therapy."

PRACTICAL PROTOCOL (van Winkelhoff et al. and Slots, as cited in Antibiotics and Antiseptics):

STEP 1: Initial periodontal therapy - thorough mechanical root debridement 
        ± surgical access if needed
        ± supplemental subgingivally applied broad-spectrum antiseptic agents
        
STEP 2: 1 to 3 months post-mechanical therapy - clinical response evaluation
        + Microbiological examination of subgingival microbiota
        (to determine presence and level of remaining putative periodontal pathogens)
        
STEP 3: Antibiotics prescribed on basis of:
        - Clinical need for further treatment
        - Microbiological findings
        - Medical status and current medications
        → SHORT-TERM HIGH-DOSE ANTIBIOTIC REGIMENS should be favored
        
STEP 4: 1-3 months post-antimicrobial therapy:
        Another microbiological test may be warranted
        → Verify subgingival elimination of target pathogens
        → Screen for possible superinfecting organisms
        (High levels of viridans streptococci and Actinomyces sp. = suggestive of periodontal health)
        
STEP 5: Resolution of periodontal infection →
        Patient placed on individually tailored maintenance care program
        (Good patient home plaque control essential for long-term success)
        
STEP 6: Screening for and eradication of exogenous pathogens 
        (A. actinomycetemcomitans and P. gingivalis) in FAMILY MEMBERS
        → Prevent reinfection and possible recurrence of disease

---

SECTION XIV: DECISION TREE FOR ANTIBIOTIC THERAPY IN AgP

DIAGNOSIS: Aggressive Periodontitis
              |
              ↓
    SRP (Initial Therapy)
              |
         ┌────┴────┐
     Resolution    Nonresolution
         |              |
    SPT/Maintenance   ┌─────────────┐
                      |             |
              Systemic Antibiotics   Local Delivery
                      |
                 ┌────┴────┐
             Resolution   Nonresolution
                 |              |
             SPT/Maintenance   Surgery
                                   |
                             ┌─────┴─────┐
                       Local+Systemic   Local Delivery
                       Antibiotics          |
                             |          Resolution→SPT
                        ┌────┴────┐     Nonresolution→Surgery
                    Resolution  Nonresolution
                        |            |
                       SPT         Surgery

---

SECTION XV: SURGICAL RESECTIVE THERAPY - SPECIAL CONSIDERATIONS

• Resective periodontal surgery can be effective to reduce or eliminate pocket depth in patients with aggressive periodontitis.
• However, "it may be difficult to accomplish if adjacent teeth are unaffected, as often seen in cases of localized aggressive periodontitis."
• If a significant height discrepancy exists between the periodontal support of the affected tooth and the adjacent unaffected tooth, the gingival transition (following the bone) will often result in deep probing pocket depth around the affected tooth despite surgical efforts.
• "It is important to realize the limitations of surgical therapy and to appreciate the possible risk that surgical therapy may further compromise teeth that are mobile because of extensive loss of periodontal support."
• In a patient with severe horizontal bone loss, surgical resective therapy may result in increased tooth mobility - a nonsurgical approach may be indicated.
• "Careful evaluation of the risks versus the benefits of surgery must be considered on a case-by-case basis."

---

SECTION XVI: REGENERATIVE THERAPY - SPECIAL CONSIDERATIONS

16.1 Potential for Regeneration

• "Most of the success and predictability of periodontal regeneration have been achieved in patients with chronic periodontitis; much less evidence is available about the use of periodontal regeneration for patients with aggressive periodontitis."
• Case reports have demonstrated regenerative potential in LAP patients (Dodson et al. - 19-year-old male with severe bone loss around mandibular incisor; using open-flap debridement, root surface conditioning with tetracycline solution, and allogenic bone graft reconstituted with tetracycline powder achieved: PPD reduction from 9-12 mm to 1-3 mm; bone fill ~80%).
• "This case illustrates the potential for healing of severe defects in patients with localized aggressive periodontitis, especially when local factors are controlled and sound surgical principles are followed."

16.2 Success Factors Cited

• Probable transition of disease activity from aggressive to chronic
• Tooth stabilization before surgery
• Sound surgical management of hard and soft tissues
• Good postoperative care

16.3 Limitations

• "Although the potential for regeneration in patients with aggressive periodontitis appears to be good, expectations are limited for patients with severe bone loss."
• The potential for bone fill and periodontal regeneration may be poor if bone loss is horizontal and if it has progressed to involve furcations.
• "The usual criteria of case selection and sound principles of surgical management for regenerative therapy apply equally to cases of aggressive periodontitis."

16.4 Enamel Matrix Protein (Emdogain)

• A systematic review concluded that treatment with enamel matrix protein can improve probing attachment level (mean difference, 1.3 mm) and probing pocket depth (mean difference, 1.0 mm) compared with flap debridement alone.

---

SECTION XVII: HOST MODULATION THERAPY - SPECIAL CONSIDERATION

17.1 Rationale

• "Currently, the influence of the host immune response in the pathogenesis of periodontitis is well known. Variations in host response between individuals are greatly responsible for observed differences in disease severity. This is especially true for individuals with aggressive periodontitis."
• "A novel approach in the treatment of aggressive periodontitis and difficult-to-control forms of periodontal disease is the administration of agents that modulate the host response."

17.2 Subantimicrobial-Dose Doxycycline (SDD) - Periostat

• "The use of subantimicrobial-dose doxycycline (SDD) may help to prevent the destruction of the periodontal attachment by controlling the activation of matrix metalloproteinases, primarily collagenase and gelatinase, from both infiltrating cells and resident cells of the periodontium, primarily the neutrophils."
• "SDD as an adjunct to repeated mechanical debridement resulted in clinical improvement in patients with generalized aggressive periodontitis." More than 50% of the patients in this study were smokers.

17.3 NSAIDs as Host Modulators

• Flurbiprofen, indomethacin, and naproxen may reduce inflammatory mediator production.
• Further research needs to be done to substantiate the effects of these agents.

---

SECTION XVIII: TREATMENT PLANNING AND RESTORATIVE CONSIDERATIONS

• "Successful management of patients with aggressive periodontitis must include tooth replacement as part of the treatment plan."
• "In some advanced cases of aggressive periodontitis, the overall treatment success for the patient may be enhanced if severely compromised teeth are extracted. The outcome of treatment for these teeth is limited, and more importantly, the retention of severely diseased teeth over time may result in additional bone loss."
• "The risk of further bone loss is even a greater concern now with the current success and predictability of dental implants."
• Teeth with moderate to advanced periodontal attachment loss and bone loss often have a poor prognosis and pose the most difficult challenge.
• Some teeth should be extracted; however, other teeth may be pivotal to the stability of that individual's dentition, and thus it may be desirable to attempt treatment to maintain them.

---

SECTION XIX: DENTAL IMPLANTS IN PATIENTS WITH AgP - SPECIAL CONSIDERATION

• "These therapies (implant placement) all seem to have a good prognosis in patients with aggressive periodontitis."
• However, prior to implant placement, thorough periodontal treatment must arrest disease activity.
• Mengel & Flores-de-Jacoby demonstrated outcomes in implants in patients treated for generalized aggressive and chronic periodontitis in a 3-year prospective longitudinal study.
• The risk of peri-implantitis in patients with a history of AgP must be considered and SPT intensified.

---

SECTION XX: SUPPORTIVE PERIODONTAL THERAPY (SPT) / MAINTENANCE

Special Considerations in AgP Maintenance:

1. Frequent maintenance intervals - more frequent than for chronic periodontitis
2. "After resolution of the periodontal infection, the patient should be placed on an individually tailored maintenance care program."
3. "Good patient home plaque control after systemic antimicrobial therapy is essential for long-term treatment success."
4. "Recurrence of progressive disease may prompt additional microbiological testing and further therapy targeting the specific periodontal pathogens involved."
5. Screening of family members for A. actinomycetemcomitans and P. gingivalis should be considered.

---

SECTION XXI: MICROBIOLOGICAL CONSIDERATIONS AND TESTING

21.1 Key Pathogens in AgP

21.2 A. actinomycetemcomitans - Why It Matters for Treatment

• Leukotoxin: Destroys PMNs and macrophages
• Bacteriocin: Inhibits growth of beneficial species
• Immunosuppressive factors: Inhibit IgG and IgM production
• Collagenase: Causes degradation of collagen
• Chemotactic inhibition factors: Inhibit neutrophil chemotaxis
• Tissue invasiveness: Bacteria located within gingival epithelium and connective tissue - mechanical debridement alone cannot eliminate it

21.3 Role of Microbiological Analysis

• Samples taken at the beginning of an appointment before instrumentation of the pocket
• Supragingival plaque removed; endodontic paper point inserted subgingivally into deepest pockets
• Placed in reduced transfer fluid or a sterile transfer tube
• "At this time, there are scant data to suggest that microbial identification from a plaque sample can be used to clinically improve the periodontal condition of the patient."

---

SECTION XXII: FAMILIAL/GENETIC CONSIDERATIONS AS SPECIAL TREATMENT FACTOR

• "Aggressive periodontitis aggregates strongly in families."
• Periodontal disease has been found in different family members; the occurrence of aggressive and chronic periodontitis has been investigated in families with a history of one or more family members with periodontitis.
• "Screening for and eradication of exogenous pathogens (A. actinomycetemcomitans and P. gingivalis) in family members might be considered to prevent reinfection and possible recurrence of disease."
• Familial transmission (intraoral transmission) via saliva is documented: "Spread of A. actinomycetemcomitans via periodontal probes in patients with localized aggressive periodontitis."
• The significance of this transmission lies in reinfection of previously treated sites.

---

SECTION XXIII: COMPREHENSIVE TREATMENT FLOWCHART FOR AgP

DIAGNOSIS OF AGGRESSIVE PERIODONTITIS
(LAP / GAP - Now: Grade C Periodontitis)
                    |
                    ↓
┌─────────────────────────────────────────┐
│          PHASE I: INITIAL THERAPY        │
│ • Patient education + OHI                │
│ • Full-mouth SRP (preferably within 1 wk)│
│ • Systemic antibiotics (concurrent):     │
│   - Amoxicillin 250-500 mg + Metro-      │
│     nidazole 250-500 mg TDS x 7-8 days   │
│   (OR tetracycline 250 mg QID x 2 wks)   │
│ • Full-mouth disinfection protocol       │
└─────────────────────────────────────────┘
                    |
              4-6 weeks
                    ↓
        REASSESSMENT / RE-EVALUATION
                    |
         ┌──────────┴──────────┐
      Resolution           Nonresolution
         |                      |
    Continue SPT         ┌──────┴───────┐
    (frequent recall) Systemic     Consider
                     workup         Microbiological
                     PMN/host       testing
                     function          |
                                  Targeted AB
                                  therapy
                                       |
                                  ┌────┴────┐
                                Residual    ≥5mm pockets
                                health      Angular defects
                                   |              |
                                  SPT         PHASE II SURGERY
                                         ┌───────────────────┐
                                         │ • Resective OR     │
                                         │ • Regenerative     │
                                         │ (GTR/Bone graft/  │
                                         │  Emdogain)        │
                                         │ + Adjunct AB      │
                                         └───────────────────┘
                                                    |
                                              Resolution
                                                    |
                               ┌────────────────────┴──────────────┐
                               │    PHASE III: SPT (Maintenance)    │
                               │ • Frequent recall (every 3 months) │
                               │ • OHI reinforcement                │
                               │ • Microbiological monitoring       │
                               │ • Screen + treat family members    │
                               │ • Tooth replacement (implants)     │
                               │   if teeth lost                    │
                               └───────────────────────────────────┘

---

SECTION XXIV: COMPARISON OF VIEWPOINTS FROM DIFFERENT REFERENCES

TABLE: Differing/Evolving Positions Across References

---

SECTION XXV: SUMMARY - SPECIAL CONSIDERATIONS AT A GLANCE

TABLE: Summary of Special Considerations in Treatment of AgP

---

SECTION XXVI: EXAMINER'S KEY KEYWORDS COMPILATION

• Aggressive periodontitis / Localized (LAP) / Generalized (GAP)
• Grade C Periodontitis (2018 classification)
• Molar-incisor pattern (2018 term for LAP)
• Aggregatibacter actinomycetemcomitans (Aa) / tissue invasiveness
• PMN chemotaxis defect / neutrophil dysfunction
• Familial aggregation
• Unpredictable response to conventional therapy
• "Burnout" of LAP / spontaneous remission
• Logical and regimented approach
• Early detection / early diagnosis
• Systemic antibiotics adjunct to SRP
• Amoxicillin + Metronidazole (current preferred combination)
• Tetracycline resistance / replaced by combinations
• Subantimicrobial-dose doxycycline (SDD) / Periostat / MMP inhibition
• Anticollagenase effect of tetracyclines
• Full-mouth disinfection (one-stage, within 24 hours)
• Regenerative therapy / tetracycline root conditioning
• Resective surgery limitations in LAP
• Treatment plan includes tooth replacement + implants
• SPT / maintenance (frequent recall)
• Screening family members for Aa
• Microbiological testing / paper point sampling
• Penicillin allergy → ciprofloxacin/clindamycin
• Short-term high-dose antibiotic regimens favored
• "More severe disease and deeper pocket → better antibiotic response"

---

1. Newman MG, Takei HH, Klokkevold PR, Carranza FA. Newman and Carranza's Clinical Periodontology and Implantology, 14th Edition. Elsevier, 2023. (Chapter 53: Chemotherapy)
2. Carranza FA, Newman MG, Takei HH, Klokkevold PR. Carranza's Clinical Periodontology, 10th Edition. (Chapter 46: Aggressive Periodontitis Treatment)
3. Flemmig TF, Slots J. Antibiotics and Antiseptics in Periodontal Therapy. (Chapter 3: Systemic Use of Antibiotics)
4. Lindhe J, Lang NP, Karring T. Clinical Periodontology and Implant Dentistry, 6th Edition. (Chapter 21: Aggressive Periodontitis)
5. Reddy S. Essentials of Clinical Periodontology and Periodontics. (Chapter 21: Periodontal Diseases in Children)